A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alopecia Areata

In brief

A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.

Key facts

Study ID

NCT02553330

Run by

Incyte Corporation

People needed

90

Starts

2015-11-18

Expected to finish

2017-10-03

Last updated by the study team

2020-12-16

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of AA
• Duration and extent of current episode of AA
• Evidence of active hair loss

You may not qualify if…

• Evidence of diffuse, spontaneous terminal hair regrowth
• Receipt of treatment known to potentially affect the course of AA within last month

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Hot Springs, Arkansas, United States
• Study site — New Haven, Connecticut, United States
• Study site — Trumbull, Connecticut, United States
• Study site — Miami, Florida, United States
• Study site — Beverly, Massachusetts, United States
• Study site — Boston, Massachusetts, United States
• Study site — Clinton Township, Michigan, United States
• Study site — Fort Gratiot, Michigan, United States
• Study site — Fridley, Minnesota, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Cleveland, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Austin, Texas, United States
• Study site — Houston, Texas, United States
• Study site — Katy, Texas, United States
• Study site — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.